EureKare

DNA Script SAS, founded in 2014 and based in Paris, France, specializes in synthetic biology tools and innovative DNA synthesis technology. The company has developed a groundbreaking enzymatic technology that powers the SYNTAX, the world's first benchtop DNA printer. This device allows laboratories to produce synthetic oligonucleotides on-site, significantly enhancing workflow control and expediting access to results. By employing an efficient biochemical process for nucleic acid synthesis, DNA Script enables researchers to rapidly generate essential genomic materials, such as oligonucleotides, which are crucial for genomics and molecular biology applications. Through its advancements, DNA Script aims to facilitate breakthroughs in life sciences and human health.

Gynov is dedicated to developing innovative solutions for women's health issues, particularly through the production of nutritional supplements. The company focuses on the scientific application of dietary supplements, utilizing carefully selected ingredients to address the diverse health needs of women during various life stages, including puberty, pregnancy, postpartum, and peri- and post-menopause. By employing a multi-target and holistic approach, Gynov aims to provide scientifically researched products that support women's health throughout their lives.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.

Omne Possibile is a technology that will outperform current DNA and RNA technologies. They offer the transformative power of XNA in areas including healthcare, information technology, and smart materials. They provide services for XNA development: chemical synthesis, genetics, directed evolution of enzymes and genomes, automated design of molecules, and bioproduction pathways.